share_log

Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53

Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53

奥本海默以跑赢大盘的评级开始对Kymera Therapeutics进行报道,宣布目标股价为53美元
Moomoo 24/7 ·  04/22 07:28

Oppenheimer analyst Jeff Jones initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $53.

奥本海默分析师杰夫·琼斯开始对Kymera Therapeutics(纳斯达克股票代码:KYMR)进行报道,评级为跑赢大盘,并宣布目标股价为53美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发